RxDoctor Payments Data

Christina Reuss, MD

Cardiovascular Disease · Scottsdale, AZNPI 1386623080

Payments from drug & device makers

$8,595in general payments, 2019–2025

Across 337 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Edwards Lifesciences$1K
  • Amgen$712
  • Johnson & Johnson$548
  • Abbott$430
  • Siemens Medical Solutions USA, Inc.$320
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$471%
  • Travel & lodging$5737%
  • Food & beverage$7,96093%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,595 in reported general payments places this provider in the 70th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$242,216
Medicare patients
875
Services billed
2,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$124,608
EntrestoSacubitril/Valsartan80$83,435
Repatha SureclickEvolocumab88$65,355
XareltoRivaroxaban49$64,598
Praluent PenAlirocumab39$29,908
JardianceEmpagliflozin14$14,755
NexletolBempedoic Acid14$9,501
NexlizetBempedoic Acid/Ezetimibe11$8,168
Ezetimibe261$6,395
Metoprolol Succinate396$5,643
Nebivolol Hcl98$4,933
Rosuvastatin Calcium408$4,478
Losartan Potassium259$2,896
Amlodipine Besylate362$2,209
Atorvastatin Calcium240$1,969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$297$124,608118 claims
NovartisEntresto$1,378$83,43580 claims
Johnson & JohnsonXarelto$548$64,59849 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$120$17,66925 claims
Boehringer IngelheimJardiance$192$14,75514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →